You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 107 No. 2, August 1973 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Cell-Mediated Immunity to Human Tumors

Abrogation by Serum Factors and Nonspecific Effects of Oral BCG Therapy

Rudolf E. Falk, MD; Paul Mann, MSc; Bernard Langer, MD

AMA Arch Surg. 1973;107(2):261-265.


Abstract

The reactivity of peripheral blood leukocytes from patients with carcinoma of the gastrointestinal tract and malignant melanoma was assessed by the leukocyte migration technique to membrane fractions of histologically similar and unrelated tumors. Inhibition of migration was observed when the tumor membranes were derived from histologically similar tumors but not with those from unrelated tumors. Normal volunteers' leukocytes failed to inhibit with either type of tumor membrane antigen.

Inhibition of migration was noted when the leukocytes were cultured in serum-free medium. Autologous serum produced complete abrogation of the response, but decreased inhibition of migration was also noted when allogeneic serum was added to the culture medium.

Seven patients with disseminated melanoma were treated with BCG therapy administered repeatedly by the oral route. This type of treatment effected a regression in three of seven patients and had prevented tumor progression in an additional two patients. No alteration in the reactivity of these patients' leukocytes to tumor membrane antigens was noted during the course of the therapy.



Author Affiliations

Toronto

From the Department of Surgery (Drs. Falk and Langer), Institute of Immunology (Dr. Falk), and Institute of Medical Science (Drs. Falk and Mann), University of Toronto.


Footnotes

Accepted for publication March 30, 1973.

Read before the 30th annual meeting of the Central Surgical Association, Toronto, Feb 24, 1973.

Reprint requests to Clinical Science Division, Medical Sciences Building, University of Toronto, Toronto, Ontario (Dr. Falk).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1973 American Medical Association. All Rights Reserved.